Quarterly Activities Report/Appendix 4C Cashflow Statement
Filed with ASX · · 11 pages · English
Summary by 6ix AI
The report highlights the acceptance of registration dossiers for two products by the TGA and the expansion of its commercial agreements to five, covering various therapeutic areas. Subsequent to the quarter, Algorae secured a public hospital supply contract and received positive validation results from its drug combination program, indicating progress in its strategic goals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- Peter Mac Testing Validates AlgoraeOS v2
- Updated - NSW Health Public Hospital Supply Contract
- Algorae Awarded NSW Health Public Hospital Supply Contract
- Algorae Expands AI Drug Combination Pipeline
- 1AI Executes License & Supply Agreement with Torrent Pharma
Later from Algorae Pharmaceuticals
- Appendix 4E and 2026 Annual Report
- Peter Mac partners with Algorae on 3rd AI validation program
- Algorae executes Licence & Supply Agreement with Umedica
- Quarterly Activities Report and Appendix 4C Cash Flow Report
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals